- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00238992
Study of Enteric-coated Mycophenolate Sodium (EC-MPS) With Steroid Withdrawal vs EC-MPS With Standard Steroid Regimen in de Novo Renal Transplant Recipients.
A Prospective, Randomized, Open Label, Multicenter Trial of EC-MPS With Steroid Withdrawal vs EC-MPS With Standard Steroid Regimen for the Prevention of Acute Rejection Episodes in de Novo Renal Transplant Recipients.
All patients of the core study who are interested of being treated with EC-MPS will be included in an open-label extension study to collect further information on the long-term safety, tolerability and efficacy of this drug.
The purpose of this study is to evaluate the feasibility of steroid withdrawal in the setting of immunosuppression with a combination of EC-MPS, cyclosporine and steroids in de novo kidney allograft recipients.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Male or female patients undergoing first kidney transplant.
- Patients aged 18 -70 years.
- Patients receiving an ABO identical or compatible graft. Exclusion Criteria
- Multi-organ recipients (e.g. kidney and pancreas) or previous transplant with any organ other than kidney.
- Positive HBsAg test
- Pre-Transplant PRA >50% or historical PRA >75% Other protocol-defined inclusion/exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
biopsy proven acute rejection incidence at 1 year post-transplantation
|
Secondary Outcome Measures
Outcome Measure |
---|
Incidence of biopsy proven acute rejection episodes at 6 months
|
Incidence of treated rejection episodes at 6 months and 1 year
|
Incidence of steroid-resistant episodes at 6 months and 1 year
|
Patient and graft survival at 1 year
|
Cardiovascular profile (as measured by Cholesterol, HbA1, Glucose, incidence of HTA)
|
Percentage of patients free from steroids at 6 months and 1 year
|
Treatment safety
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CERL080A2405ES01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney de Novo Transplant
-
NovartisCompletedDe Novo Kidney Transplant Recipients
-
Astellas Pharma IncCompletedDe Novo Kidney Transplant PatientsChina
-
NovartisCompletedRenal Transplantation | de Novo Kidney Transplant RecipientsItaly
-
National Institute of Allergy and Infectious Diseases...Clinical Trials in Organ Transplantation; Cooperative Clinical Trials in Pediatric...CompletedKidney Transplant | Kidney Transplant Recipient | Graft Function/Survival | de Novo HLA Antibodies DevelopmentUnited States
-
University Hospital, ToursAstellas Pharma IncUnknownDe Novo Transplant DiseaseFrance
-
Rigshospitalet, DenmarkCompletedLiver Transplant Disorder | De Novo Cancer
-
Astellas Pharma Korea, Inc.Completedde Novo Liver Transplant SubjectsKorea, Republic of
-
Erasmus Medical CenterHoffmann-La RocheCompletedDe Novo Renal Transplant Recipient.France, Spain, Taiwan, Denmark, Australia, United Kingdom, Germany, Canada, Belgium, China, Sweden, Netherlands, Austria, Brazil, Estonia, Lithuania, Norway, Poland, Venezuela
-
Astellas Pharma IncCompletedDe Novo Kidney TransplantationBelgium, France, Netherlands, Spain, Sweden, Austria, Italy, Germany, United Kingdom, Hungary, Poland, Czech Republic
-
NovartisCompleted
Clinical Trials on Enteric-coated Mycophenolate sodium (EC-MPS)
-
NovartisCompletedMaintenance Kidney TransplantSwitzerland
-
Novartis PharmaceuticalsCompletedRenal TransplantKorea, Republic of
-
NovartisCompletedDe Novo Kidney Transplant Recipients
-
NovartisCompleted
-
Novartis PharmaceuticalsCompleted
-
NovartisCompleted
-
NovartisCompleted
-
Novartis PharmaceuticalsCompletedRenal TransplantationUnited States